

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – Q2 ACTIVITY & COMPANY UPDATE

- **Q2 FY24 highlights: total cash receipts of \$4.8M (Q2 FY23: \$3.3M)**
- **First quarter of sales contribution from Face MediGroup acquisition (\$1.6M)**
- **Record first half revenue from customers FY24 +16% vs. H1 FY23**

SYDNEY, Date 31 January 2024

Commentary on Q2 FY24 performance

The Company is pleased to update shareholders on Q2 FY24 performance.

Cash receipts from customers and other income for the quarter were \$4.8M (Q1 FY24: \$2.4M) (compared to \$3.3M Q2 FY23). This also included a cash receipt of annual R&D tax credit income of approximately \$0.2M.

December quarter included key promotional direct to consumer (D2C) activities (namely Black Friday and Cyber week). D2C sales were \$1.7M in Q2 FY24 (Q2 FY23: \$0.2M) and on a like for like basis, the B2B business generated revenue of \$2.5M (up 4% on pcp).

The acquisition of Face MediGroup, which was completed at the end of September 2023, supported cash receipts in Q2 FY24 by approximately \$1.6M.

Total cash payments made to suppliers and employees in Q2 FY24 were approximately \$5.0M (Q2 FY23: \$3.0M) and one-off acquisition costs in the period were approximately \$0.1M. Net operating cash outflows for the Group in Q2 FY24 were approximately \$0.3M (Q1 FY24: \$0.7M, cash outflow) and \$0.3M cash inflow in Q2 FY23.

Payments to related parties in Q2 FY24 totalled \$141K and related to remuneration paid to AN1 Directors.

Update on H1 FY24 performance

The Company is pleased to announce its preliminary unaudited financial results for H1 FY24:

- Total revenue from customers H1 FY24 \$6.2M vs. H1 FY23 \$5.3M, improved by 16%
- EBITDA H1 FY24 \$1.0M (loss) vs. H1 FY23 \$1.5M (loss), reduced by 30%

H1 FY24 included initial revenue and EBITDA losses from the Face MediGroup acquisition prior to integration. The full benefits of business restructuring and integration are expected to commence realising from January 2024.

Further details and audited results for H1 FY24 will be provided in the Appendix 4D and Half Year report to be released in February 2024.

Approved for release by the Board of Directors.

ANAGENICS

Scott Greasley
CEO
+61 412 308 263
info@anagenics.com

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity
ANAGENICS LIMITED
ABN
69 111 304 119
Quarter ended ("current quarter")
31 December 2023

Consolidated statement of cash flows	Current quarter (3 months) \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4,585	6,942
1.2 Payments for		
(a) research and development	(5)	(9)
(b) product manufacturing and operating costs	(2,054)	(3,280)
(c) advertising and marketing	(527)	(775)
(d) leased assets	-	-
(e) staff and director costs	(1,229)	(2,240)
(f) administration and corporate costs	(1,227)	(1,801)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	6	15
1.5 Interest and other costs of finance paid	(15)	(15)
1.6 Income taxes (paid) / refunded	9	6
1.7 Government grants and tax incentives	177	177
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(280)	(980)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities (net)	-	-
(b) businesses	(100)	(100)
(c) property, plant and equipment	(37)	(84)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter (3 months) \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities (net)	-	49
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(137)	(135)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings & leasing	(26)	(104)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(26)	(104)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,795	2,567
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(280)	(980)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(137)	(135)

Consolidated statement of cash flows		Current quarter (3 months) \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(26)	(104)
4.5	Effect of movement in exchange rates on cash held	(2)	2
4.6	Cash and cash equivalents at end of period	1,350	1,350

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,210	1,657
5.2	Call deposits	140	138
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,350	1,795

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	141
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
N/A		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(280)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,350
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	1,350
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.8
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:31 January 2024.....

Authorised by: **Board of Directors – Anagenics Limited**.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.